# Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A

> **NCT03815318** · PHASE3 · COMPLETED · sponsor: **Sinocelltech Ltd.** · enrollment: 73 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Recombinant Human Coagulation FVIII

## Key facts

- **NCT ID:** NCT03815318
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-21
- **Primary completion:** 2020-01-16
- **Final completion:** 2020-01-16
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2020-02-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03815318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03815318, "Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03815318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*